EcoDrugPlus

Dopamine Receptor D1b

Ensembl ID : ENSAPOG00000013989
Gene Symbol: DRD1B
1 Cross references
200 Possible Orthologues:

Dopamine Receptor D2

Ensembl ID : ENSAPOG00000005343
Gene Symbol: DRD2
3 Cross references
204 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSAPOG00000001962
Gene Symbol: DRD3
3 Cross references
203 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSAPOG00000022995
Gene Symbol: DRD4
3 Cross references
173 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSAPOG00000007164
Gene Symbol: DRD5
1 Cross references
158 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSAPOG00000005281
Gene Symbol: LOC110950007
3 Cross references
218 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSAPOG00000004735
Gene Symbol: LOC110967143
3 Cross references
202 Possible Orthologues:

Dual Specificity Protein Kinase Ttk-Like

Ensembl ID : ENSAPOG00000006713
Gene Symbol: LOC110967065
3 Cross references
204 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSAPOG00000000191
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSAPOG00000011153
Gene Symbol: EGLN1
3 Cross references
216 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSAPOG00000007757
Gene Symbol: EGLN3
3 Cross references
200 Possible Orthologues:

Endothelial Pas Domain-Containing Protein 1-Like

Ensembl ID : ENSAPOG00000004946
Gene Symbol: LOC110957545
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).